Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340

Ann Oncol. 2020 Mar;31(3):444-445. doi: 10.1016/j.annonc.2020.01.004. Epub 2020 Jan 31.

NO ABSTRACT

PMID:32067691 | DOI:10.1016/j.annonc.2020.01.004

No abstract

D Mavroudis, E Saloustros, N Malamos, S Kakolyris, I Boukovinas, P Papakotoulas, N Kentepozidis, N Ziras, V Georgoulias, Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece

2020-02-19

Annals of oncology : official journal of the European Society for Medical Oncology

View Publication

Previous PostGuidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Next PostFrequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study